SST and obesity due to melanocortin 4 receptor deficiency: In this context, current evidence suggests that SST and its analogues, through binding to different SSTR subtypes on the pancreatic β-cells, decrease the release of insulin, which may be beneficial in the treatment of obesity [209,215,216,218,219,220].